AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 273: R1572-R1579, 1997;
0363-6119/97 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ernsberger, P.
Right arrow Articles by Haxhiu, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ernsberger, P.
Right arrow Articles by Haxhiu, M. A.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 273, Issue 5 1572-R1579, Copyright © 1997 by American Physiological Society

ARTICLES

The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla

P. Ernsberger and M. A. Haxhiu
Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio 44106-4982, USA.

I1-imidazoline-binding sites fulfill all essential criteria for identification as receptors, including specificity of binding, association with physiological functions, appropriate anatomic and cellular and subcellular localization, and specific cell signaling pathways. Moreover, binding affinities correlate with functional drug responses. The evidence linking I1 receptors to vasodepression includes expression in RVLM and consistent correlations between vasodepressor potency in humans and animals and I1 binding affinity. Some I1 agonists are antagonists at alpha 2-adrenergic receptors (alpha 2AR), and these elicit vasodepression in RVLM. Potent alpha 2-agonists with phenylethylamine or guanidine structures are inactive in RVLM, yet highly effective in nucleus of the solitary tract, a region with well-defined alpha 2-mediated vasodepressor responses. Selective I1 agonists are used clinically to lower blood pressure with minimal alpha 2-mediated sedation. Moreover, when microinjected into the RVLM only antagonists active at I1 receptors can block the vasodepressor action of either local or systemic imidazolines. RVLM alpha 2-blockade has no effect. Some reports appear to conflict with the I1 receptor hypothesis; but these reports often make incorrect assumptions regarding drug specificity, overlook systemic effects of alpha 2-antagonists, or inappropriately analyze data. Blockade of gamma-aminobutyric acid (GABA) receptors blocks the vasodepressor action of imidazolines, implying a multisynaptic pathway. Thus imidazolines act via I1 receptors in RVLM to lower blood pressure, although alpha 2AR are also important, especially in NTS.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. Zhang and A. A. Abdel-Rahman
Inhibition of Nischarin Expression Attenuates Rilmenidine-Evoked Hypotension and Phosphorylated Extracellular Signal-Regulated Kinase 1/2 Production in the Rostral Ventrolateral Medulla of Rats
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. G. Wilson, S. Akhter, C. A. Mayer, P. Kc, K. V. Balan, P. Ernsberger, and M. A. Haxhiu
Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets
J Appl Physiol, December 1, 2007; 103(6): 2095 - 2104.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online